

Neuroprotective Effect of Early Treatment with Pioglitazone and Vitamin E Acetate in Alloxan Induced Diabetes in Rats

A.S.Morani, S.L.Bodhankar

Department of Pharmacology, Bharati Vidyapeeth University, Poona College of Pharmacy, Pune 411 038, Maharashtra, India

Summary

Neuropathic pain in diabetics is characterized by both hyperalgesia and allodynia. This is attributed to both uncontrolled glycemia and the further complications which it leads to. We evaluated the effect of concurrent administration of Pioglitazone along with vitamin E acetate in diabetic rats. The parameters used were hyperalgesia produced by tail immersion (hot water), hot plate method and allodynia produced by tail immersion in cold water. A gradual reduction in weight and locomotor activity along with a lowered pain latency was observed in alloxan treated animals. Whereas no change in pain latency was observed in drug treated animals indicating that the early treatment with pioglitazone and vitamin E acetate could protect the animal from early hyperalgesia and allodynia produced by alloxan induced diabetes in rats.

Keywords: Pioglitazone, Vitamin E , Alloxan induced diabetic neuropathy, rats.

Shortened Tittle: Vitamin E acetate and Pioglitazone in alloxan induced diabetic neuropathy....

Correspondance:

Aashish Morani,
Department of Pharmacology, Bharati Vidyapeeth University, Poona College of Pharmacy, Erendwane, Pune 411 038,
Maharashtra, India.
E-mail: aashu110@gmail.com
Telefax: 91 20 2543 72 37.

Introduction

Diabetes mellitus is associated with several long term complications, prominent among them is peripheral neuropathy. Spontaneous pain, allodynia and hyperalgesia are frequently encountered in diabetic patients [1,2,3,4,5]. A review of published work on painful diabetic neuropathy suggests that a significant degree of neuropathic pain is more likely to occur in patients with uncontrolled diabetes and has been proposed that acute biochemical alterations in neural tissues might result from prolonged hyperglycemia and could contribute to the development of diabetic neuropathy [1,6]. Four main molecular mechanisms, namely increased polyol pathway flux, increased advanced glycation end-product (AGE) formation, activation of protein kinase C (PKC) isoforms and increased hexosamine pathway flux have been implicated in glucose-mediated vascular damage and all seems to reflect a single hyperglycemia-induced process of overproduction of superoxide by the mitochondrial electron-transport chain [7]. Clinical and experimental studies have revealed that reactive oxidant species (ROS) play's a significant role in pathophysiology of neuropathic pain in diabetes [2]. Adequate metabolic control may reduce the symptoms of painful diabetic neuropathy [6]. Reactive oxidant species (ROS) are critically involved in the development and maintenance of neuropathic pain. Studies suggest that systemic administration of Non-toxic doses of free radical scavengers could be useful for treatment of neuropathic pain [7]. Also deficiency of some vitamins in the diet could lead to neuropathic pain [8]. Vitamin E is considered the most effective liposoluble antioxidant found in the human biological system. It interacts with free radicals and prevents lipid peroxidation. [9,10]. Clinically, VE supplementation led to electrophysiological recovery of sensory conduction and evoked potentials [11]. Also VE supplementation in cancer patients showed it may have an important neuroprotective

effects [12]. The objective of this study was to evaluate the effect of early treatment with the co-administration of pioglitazone with vitamin E acetate in prevention of neuropathic complications in alloxan induced diabetic rats.

Material and Methods

Animals: Adult male Wistar rats (200-250g) were obtained from National Toxicology Centre, Pune, India. On arrival, the animals were placed at random and allocated to treatment groups in polypropylene cages with paddy husk as bedding. Animals were housed at a temperature of $24\pm 2^{\circ}\text{C}$ and relative humidity of 30-70%. A 12:12 hr light : dark cycle was followed. All animals had free access to water and standard pellet laboratory animal diet. Animals were acclimatized to laboratory conditions before the experiments that were carried out between 0900 and 1700 hr. All the experimental procedure used in this study were reviewed and carried out in accordance with that described by Zimmerman et al [12] and approved by Institutional Animal Ethics Committee for Poona College of Pharmacy, Pune, India.

Preparation of the drug solution

Pyridoxine hydrochloride:- An emulsion of vitamin E acetate (Himedia) was prepared using 1% tween 80 as an emulsifying agent. The volume was made by using distilled water. The drug solution was stored in air tight bottles at room temperature in a cool and dry place away from moisture and sunlight. The solutions were freshly prepared for daily administration.

Pioglitasonone: Solution was prepared by dissolving pioglitasonone (Alembic) in distilled water. The drug was prepared daily and was stored at room temperature away from sunlight and moisture. The volume of drug solution were calculated based upon the body weight of the animal.

Alloxan treatment: Following a 48 hr fast, the animals received intraperitoneal (i.p) injections of alloxan monohydrate (120mg/kg) dissolved in 0.9% sodium chloride. Control animals received i.p injections of 0.9% sodium chloride. Within 48 hrs following alloxan administration, blood glucose concentration were estimated by enzymatic GOD-POD (glucose oxidase-peroxidase) diagnostic kit method (Accurex) [13, 14]. The rats having serum glucose levels more than 250mg/dl were selected and used for the present study. After the induction of diabetes in the animals diabetic rats were randomly selected into three groups of 8 animals each. ie. control (treated with 1% tween 80 solution), diabetic untreated (DU) and diabetic animals treated with combination of pioglitasonone (10mg/kg,O.D) with vitamin E acetate (50mg/kg, O.D) (DPE). Treatment begun from the day of BSL detection after the alloxan treatment. Body weight was checked daily and serum glucose level were measured on 15th and 30th day of study.

Assessment of thermal hyperalgesia and cold allodynia [2]

Tail immersion (warm water) test: Tail of rat was immersed in a warm water ($47\pm 1^{\circ}\text{C}$) bath until tail withdrawal (flicking response) or signs of struggle were observed (cut-off 15 sec).

Tail-immersion (cold water) test: The procedure was same as warm water test but the temperature of water was set at $10\pm 0.5^{\circ}\text{C}$, a temperature that is normally innocuous. The cut-off time was 15 sec.

Hot plate test: In this test, animals were individually placed on a hot plate (Ugo Basile hot plate, Versace Italy) with the temperature adjusted to $55\pm 1^{\circ}\text{C}$. The latency to the first sign of paw licking or jump response to avoid heat pain was taken as an index of pain threshold. The cut-off time was kept 10 sec so as to avoid damage to the paw. Both hyperalgesia and allodynia were assessed weekly till the end of the study.

Statistical Analysis

Data was expressed as mean \pm SEM of animals in each group. To determine the statistical significance, ANOVA followed by Tukey-Kramer test (Instat/ Graphpad) was used. Differences between means were considered statistically significant if $p < 0.001$.

Results

Effect of DPE on blood sugar level (BSL) in alloxan induced diabetes in rats.

Blood sugar levels of control group of animals did not alter throughout the experiment. In DU group blood glucose levels increased steadily on day 15th (346.19 ± 6.86 mg/dl) and day 30th (384.81 ± 4.91 mg/dl) after alloxan treatment indicating the incidence of diabetes in the animals throughout the experiment. There was no significant difference in BSL of DPE treated animals (298.72 ± 7.12 mg/dl) 48 hrs post alloxan treatment as compared to DU group of animals (269.4 ± 8.16 mg/dl) indicating the incidence of diabetes. But a

gradual reduction in the BSL of DPE group was observed on day 15th (132.64±5.6 mg/dl) and day 30th (120.41±6.78 mg/dl) indicating glycemic controls by drug treatment.

Table 1. Effect of DPE on blood sugar levels (BSL) in alloxan induced diabetes in rats.

	<i>Blood sugar level in mg/dl</i>			
	<i>Pre-Alloxan treated</i>	<i>48 hr post alloxan treated</i>	<i>Day 15</i>	<i>Day 30</i>
Control	97.62 ±5.35	106.64±6.16	102.59±4.8	104.23±3.84
DU	94.51±6.21	269.4±8.16	346.19±6.86	384.81±4.91
DPE	90.2±6.81	298.72±7.12	132.64*±5.6	120.41*±6.78

*Data expressed in Mean ± S.E.M. ANOVA followed by Tukey test.. p <0.001 = *. Data of DPE was compared with that of DU. n=8.*

Effect of DPE on hyperalgesia produced by tail immersion (hot water) in alloxan induced diabetes in rats.

There was no change in tail flick latency (sec) observed in control group of animals throughout the experiment. A gradual decline in the latency was observed in DU group of animals from day 7th (8.1±0.26 s) onwards which was observed minimum on day 28th (4.1±0.76 s), indicating the presence of neuropathic pain due to diabetes. DPE group of animals recorded a reduction in latency on day 7th (9.8±0.41 s) which was followed by

increase in pain threshold time on subsequent days, indicating absence of algisia produced by tail immersion in hot water.

Table 2. Effect of DPE on hyperalgesia produced by tail immersion (hot water) in alloxan induced diabetes in rats.

<i>Tail Flick latency in seconds</i>					
	<i>Pre-Alloxan treated</i>	<i>Day 7</i>	<i>Day 14</i>	<i>Day 21</i>	<i>Day 28</i>
Normal	11.6 ±0.7	12.4 ±0.61	10.81±0.42	12.0 ±0.91	11.21±0.41
DU	10.9±0.51	8.1±0.26	6.1±0.82	5.3± 0.81	4.1±0.76
DPE	10.5±0.9	9.8±0.41	10.0*±0.47	10.4*±0.65	11.1*±0.3

*Data expressed in Mean ± S.E.M. ANOVA followed by Tukey test.. p <0.001 = *. Data of DPE was compared with that of DU. n=8.*

Effect of DPE on allodynia produced by tail immersion (cold water) in alloxan induced diabetes in rats.

No significant change in latency was observed in control group of animals throughout the study. For DU group of animals there was a gradual reduction in latency (sec) observed from day 7th (10.2±0.49 s) till day 28th (4.1±0.8 s) indicating the presence of allodynia. In the DPE group of animals, no significant lowering in pain latency was exhibited which implies the protective action of drug treatment on allodynia produced by cold water.

Table 3. Effect of DPE on allodynia produced by tail immersion (cold water) in alloxan induced diabetes in rats.

<i>Tail Flick latency in seconds</i>					
	<i>Pre-Alloxan treated</i>	<i>Day 7</i>	<i>Day 14</i>	<i>Day 21</i>	<i>Day 28</i>
Normal	13.6 ±0.41	14.1±0.21	13.2±0.6	13.9±0.36	13.0±0.7
DU	14.0±0.6	10.2±0.49	7.4±0.51	5.5± 0.94	4.1±0.8
DPE	14.1±0.28	13.6±0.91	13.0*±0.93	14.2*±0.18	13.9*±0.64

*Data expressed in Mean ± S.E.M. ANOVA followed by Tukey test.. p <0.001 = *. Data of DPE was compared with that of DU. n=8.*

Effect of DPE on thermal hyperalgesia (hot plate) in alloxan induced diabetes in rats.

No significant change in latency was observed in control group of animals throughout the study. For DU group of animals there was a gradual reduction in latency (sec) observed from day 7th (8.0±0.44 s) till day 28th (3.8±0.19 s) where the pain was observed to be maximum, indicating the presence of algesia by heat. In the drug treated group of animals, no significant lowering in pain latency was exhibited which implies the protective action of DPE on hyperalgesia produced in diabetic animals.

Table 4. Effect of DPE on thermal hyperalgesia (hot plate) in alloxan induced diabetes in rats.

	<i>latency in seconds</i>				
	<i>Pre-Alloxan treated</i>	<i>Day 7</i>	<i>Day 14</i>	<i>Day 21</i>	<i>Day 28</i>
Normal	9.8 ±0.4	9.4 ±0.16	9.7±0.34	9.7 ±0.1	9.1±0.84
DU	9.4±0.64	8.0±0.44	6.4±0.52	5.0± 0.32	3.8±0.19
DPE	9.9±0.15	9.2±0.6	9.0* ±0.8	9.3* ±0.43	9.5* ±0.12

*Data expressed in Mean ± S.E.M. ANOVA followed by Tukey test.. p <0.001 = *. Data of DPE was compared with that of DU. n=8.*

Discussion

A strong relationship exists between glycemia and diabetic microvascular complications in both type 1 and type 2 diabetes [7]. Generation of superoxide due to oxidative stress in diabetes may be responsible for vascular and neuronal complications of painful neuropathy [2]. Early in the course of diabetes, intracellular hyperglycemia causes abnormalities in blood flow and increased vascular permeability. Quantitative and qualitative abnormalities of extracellular matrix contribute to an irreversible increase in

vascular permeability. With time microvascular cell loss occurs in part as a result of programmed cell death. Hyperglycemia may also decrease production of trophic factors for endothelial and neuronal cells. Together, these changes lead to edema, ischaemia and hypoxia induced neovascularization in the retina, proteinuria, messengial matrix expansion, glomerulosclerosis in the kidney and multifocal axonal degeneration in peripheral nerves [7]. Impaired blood flow also seems to contribute to noxious stimulus hypersensitivity. Oxidative stress related reduction in perfusion is thought to play a part in cardiac autonomic dysfunction and also in small fiber sensory neuropathy [2].

Alloxan and the products of its reduction, dialuric acid, establish a redox cycle with formation of superoxide radicals. These radicals undergo dismutation to hydrogen peroxide. Thereafter highly reactive hydroxyl radicals are formed by the Fenton reaction. The action of reactive oxidant species (ROS) with a simultaneous massive increase in cytosolic calcium concentration cause rapid Beta cell destruction [15]. Early pharmaceutical intervention against the long-term consequences of hyperglycemia-induced cross-linking prevents the development of severe late complications of diabetes. Pioglitazone, a PPAR gamma receptor agonist has been approved by FDA for lowering blood sugar in type 2 diabetes. Also studies indicate that pioglitazone is a powerful inhibitor of glycation, AGE formation and cross-linking [8]. VE is considered as one of the principle protective mechanism against oxidative damage in neuronal tissue . VE is the major lipid soluble chain breaking antioxidant in the body tissues and effectively protects against neuronal damage [10,20]. Vitamin E indirectly participate in the reduction of oxidative stress in diabetic patients by its antioxidant activity [21]. Experimental studies have shown that the use of VE after Ischemia/Reperfusion injury in

animals not only attenuated the oxidative injury of the muscle cells but also reduced the formation of edema in these cells, which means that they have partial protective action [9]. Vitamin E has protective effects on the retina during retinal ischemia-reperfusion injury [22]. Also Supplementation of patients receiving cisplatin chemotherapy with vitamin E decreased the incidence and severity of peripheral neurotoxicity.[12]

It was observed that alloxan treated rats (DU) exhibited a marked increase in glycemia [Table 1] and water intake and a clear cut reduction in the progressive gain in body weight as compared to control and drug treated group (DPE). In addition, polydipsia, polyphagia, polyurea and reduced motility was also observed in DU group of animals. These results were in accordance with Aibel et al (2004). Both hyperalgesia and allodynia were established after 14 days of alloxan treatment which was observed behaviorally [Table 2,3,4]. The hyperalgesic response in tail-withdrawal test is generally attributed to central mechanisms whereas the hyperalgesic response on hot plate is attributed to the combination of both central and peripheral mechanisms [2]

Our results indicate that in untreated group of animals (DU), there was no glycemic control, which led to hyperalgesia and allodynia in the models of tail immersion (hot and cold) and hot plate method. Whereas by a proper check on blood glucose levels by pioglitazone 10 mg/kg, O.D alongwith the supplementation of vitamin E acetate 50 mg/kg, O.D protected the diabetic animals from algisia produced by noxious and non-noxious stimuli.

Hence through our findings we conclude that the onset of neuropathic complications could be prevented by early glycemic controls by pioglitazone and concurrent administration of vitamin E acetate in diabetic rats.

Acknowledgements

We thank Dr.S.S.Kadam and Dr.K.R.Mahadik (Bharati Vidyapeeth University, Poona College of Pharmacy, Pune) for their constant encouragement. We would thank Alembic Pharmaceuticals for free gift samples of pioglitazone.

Reference

1. Lee JH, Cox DJ, Mook DG and McCarty RC, Effect of hyperglycemia on pain threshold in alloxan-diabetic rats, *Pain* 40 (1990) 105-7.
2. Anjaneyulu M, Chopra K, Quercetin attenuated thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats, *Indian Journal of Experimental Biology*; 42, Aug 2004; 766-9.
3. Aubel B, Kayser V, Mauborgne A, Farre A, Hamon M, Bourgoin S, Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies, *Pain* 110 (2004), 22-32.
4. Malcangio M, Tomlinson D, A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/ diabetic rats, *Pain* 76 (1998), 151-7.
5. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR, Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin,aldose reductase inhibition and lidocaine, *Pain* 68 (1996) 293-9.

6. Kastrup J, Peterson P, Dejgard A, Angelo HR, Hilsted J, Intravenous lidocaine infusion – a new treatment of chronic painful diabetic neuropathy?, *Pain*, 28(1987) 69-75.
7. Brownlee M, Biochemistry and molecular cell biology of diabetic complications, *NATURE* (414) 13 Dec 2001.
8. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL, Evidence that pioglitazone, metformin and pentoxifyline are inhibitors of glycation, *Clinica Chemica Acta* 301 (2000) 65-77.
9. Zimmermann M, Ethical guidelines for investigators of experimental pain in conscious animals, *Pain* 16 (1983) 109-110.
10. Badole S.L, Patel N.M, Thakurdesai P.A and Bodhankar S.L, Interaction of aqueous extract of *Pleurotus pulmonarius* (Fr.) Quel-Champ with glyburide in alloxan induced diabetic mice, *eCAM Advanced Access* published March 14, 2007 Page 1-6.
11. Abdel-Barry JA, Abdel-Hassan IA, Al-Hakiem MH, Hypoglycaemic and antihyperglycaemic effects of *Trigonella foenum-graecum* leaf in normal and alloxan induced diabetic rats, *J Ethnopharmacol.* 1997 Nov;58(3):149-55
12. Szkudelski T, The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas, *Physiol. Res.* 50 (2001): 536-46.
13. Al Moutaery K, Arshaduddin M, Tariq M, Al Deeb S, Functional recovery and Vitamin E level following sciatic nerve crush injury in normal and diabetic rats, *Int J Neurosci*, 1998 Dec; 96 (3-4): 245-54.

14. Dellon AL, Dellon ES, Tassler PL, Ellefson RD and Hendrickson M, Experimental model of pyridoxine (B6) deficiency-induced neuropathy, *Ann Plast Surg*, 2001 Aug; 47(2): 153-60.
15. Silva MG, Castro AA, Ramos EAG, Peixoto E, Miranda F, Pitta GB, Costa RFB, Juliano Y, Histological and biochemical serum effects of alpha-tocopherol on ischemia/reperfusion –related injuries induced in the pelvic limb of the rat, *Acta Cirurgica Brasileira – Vol 20 (5) 2005 – 375*
16. Aabdallah DM, Eid NI, Possible neuroprotective effect of lecithin and alpha-tocopherol alone or in combination abainst ischemia/reperfusion insult in rat brain, *J Biochem Mol Toxicol*, 2004; 18(5) : 273-8.
17. Puri V, Chaudhary N, Tatke M, Prakash V, Isolated Vitamin E deficiency with demyelinating neuropathy, *Muscle Nerve*. 2005; 32(2): 230-5
18. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Monte G, Bioccio A, Leonetti C, Jandolo B, Cognetti F and Bove L, Neuroprotective effect of Vitamin E supplementation in patients treated with cisplatin chemotherapy, *Journal of Clinical Oncology*. Mar 2003 ;21(5): 927-31.
19. Ziegler D, Christoph G.H.Sohr, Jaffar Nourooz-Zadeh, Oxidative stress and antioxidant defence in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy: *Diabetes Care*, Volume 27, number 9, September 2004, 2178-83.
20. Bonnefont-Rousselot D, The role of antioxidant micronutrients in the prevention od diabetic complications, *Treat Endocrinol*. 2004; 3(1): 41-52.

21. Aydemir O, Celebi S, Yilmaz T, Yekelar H and Kukenar AS, Protective effects of Vitamin E forms (Alpha, gamma and d-alpha tocopherol Polyethylene Glycol 1000 Succinate) on retinal edema during ischemia/reperfusion injury in the guinea pig retina, *Int Ophthalmol*, 2004 Oct; 25(5-6): 283-289.
22. A.S.Morani, S.L.Bodhankar; Neuroprotective effect of pyridoxine hydrochloride in models of mononeuropathy in rats: *Pharmacologyonline 2: 147-57 (2007)*.
23. A.S.Morani, S.L.Bodhankar; Neuroprotective effect of early treatment with pioglitazone and pyridoxine hydrochloride in alloxan induced diabetes in rats; *Pharmacologyonline 2: 418-28 (2007)*.